SCHEDULE: Cormorant Asset Management Discloses 5.97% Stake in enGene

Cormorant Asset Management, LP and Bihua Chen have reported a 5.97% beneficial ownership stake in enGene Holdings Inc. common shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen have jointly reported beneficial ownership of 4,000,000 common shares of enGene Holdings Inc.
• This represents a 5.97% stake in the company's common shares.
• The ownership is held through Cormorant Funds, with Cormorant Global Healthcare Master Fund, LP having the right to receive dividends or proceeds from the sale of more than 5% of the shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of enGene Holdings Inc.
• The percentage of class is calculated based on 66,984,661 shares outstanding as of December 17, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a reputable investment firm like Cormorant Asset Management can signal confidence in enGene Holdings Inc.'s future, although the filing itself is purely a disclosure.

Positives

• A significant institutional investor, Cormorant Asset Management, has taken a substantial 5.97% stake in enGene Holdings Inc., indicating potential confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic, rather than activist, position.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing.

Risks

• No specific risks are disclosed in this Schedule 13G filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding enGene Holdings Inc.'s future performance or strategic direction.

Management Comments

• The filing includes a certification by Bihua Chen, Managing Member of Cormorant Asset Management, LP, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that a significant stake by a specialized healthcare investment firm like Cormorant Asset Management often signals a positive long-term view on the company's prospects within the biotechnology or pharmaceutical sector. Such an investment can provide a vote of confidence, potentially attracting further institutional interest in enGene Holdings Inc.

Comparison to Industry Standards

• StockSavvy.ai observes that a 5.97% stake is a substantial position for an institutional investor, placing Cormorant Asset Management among the larger shareholders of enGene Holdings Inc. For example, similar significant stakes by specialized funds in emerging biotech companies like Moderna (prior to its major growth) or BioNTech have often preceded periods of increased market attention and capital appreciation, assuming the underlying company fundamentals are strong. This level of ownership suggests a conviction beyond a mere portfolio allocation.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 5.97% stake could be viewed positively, potentially increasing investor confidence and attracting further investment.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for enGene Holdings Inc. or the reporting persons beyond the ongoing holding of the shares.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Cormorant Asset Management is a positive signal, this Schedule 13G filing primarily provides ownership information rather than operational or financial performance data. A 'hold' recommendation is appropriate as it acknowledges the positive institutional interest without making a definitive 'buy' or 'sell' call based solely on this ownership disclosure, pending further analysis of enGene Holdings Inc.'s core business and financial health.

Keywords

enGene Holdings Inc., Cormorant Asset Management, Bihua Chen, Schedule 13G, beneficial ownership, institutional investment, common shares, biotechnology, healthcare investment